Ricerca
La gestione del bambino con testicolo ritenuto
MANAGEMENT OF UNDESCENDED TESTIS: A SURVEY OF CLINICAL PRACTICE IN ITALY
Federico Marchetti1, Luca Ronfani1, Jenny Bua1, Gianluca Tornese1, Gianni Piras2, Giacomo Toffol2
1Clinica Pediatrica, Servizio di Epidemiologia e Biostatistica, Dipartimento di Chirurgia, IRCCS “Burlo Garofolo”, Trieste
2Associazione Culturale Pediatri
a nome del Gruppo di Studio italiano sul testicolo ritenuto
Aprile 2010 - pagg. 250 -258
Abstract
Background: The aims of our study were to describe the current management of cryptorchidism
among Italian family paediatricians (FP) and detect any difference from the recently
published Nordic Consensus guidelines.
Methods: An online questionnaire was filled in by 140 Italian FP from 18/20 Italian regions.
The questionnaire requested information on all children with cryptorchidism born
between 1/01/2004 and 1/01/2006, their characteristics and management.
Results: Data on 169 children with undescended testis were obtained. Among those, 24%
had at diagnosis a retractile testis, while 76% had a true cryptorchidism. Mean age at diagnosis
was 9.6 months (SD 13.2; range 0-52.8). In 16% of cases cryptorchydism resolved
spontaneously at a mean age of 25.2 months (SD 12; range 6-46.8). On the overall cases,
99 subjects (59%) underwent orchiopexy at mean age of 22.8 months (SD 10.8; range
1.2-56.4), 13% of which before 1 year of age. The intervention was performed by a
paediatric surgeon in 89% of cases, with a success rate of 91%. Orchiopexy was the first
line treatment in 82/99 cases (83%), while preceded by hormonal treatment in the
other 17 cases. Hormonal treatment was used as first line in 20% of cases with a reported
success rate of 25% (n=8/32). Overall, 18 children did not undergo any intervention
(mean age at last follow up 44.4 months; SD 12; range 20.4-62.4).
Conclusions: Our study showed an important delay in orchiopexy. Moreover, a high percentage
of children with undescended testis was treated with hormonal therapy, although
it is not recommended by the recent guidelines.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
1. Virtanen HE, Bjerknes R, Cortes D, et al. Cryptorchidism: classification, prevalence and long-term consequences. Acta Paediatr 2007;96:611-6.
2. Ghirri P, Ciulli C, Vuerich M, et al. Incidence at birth and natural history of cryptorchidism: a study of 10,730 consecutive male infants. J Endocrinol Invest 2002;25:709-15.
3. Virtanen HE, Cortes D, Rajpert-De Meyts E, et al. Development and descent of the testis in relation to cryptorchidism. Acta Paediatr 2007;96:622-7.
4. Thorsson AV, Christiansen P, Ritzén M. Efficacy and safety of hormonal treatment of cryptorchidism: current state of the art. Acta Paediatr 2007;96:628-30.
5. Thorup J, Haugen S, Kollin C, et al. Surgical treatment of undescended testes. Acta Paediatr 2007;96:631-7.
6. Ritzén EM, Bergh A, Bjerknes R, et al. Nordic consensus on treatment of undescended testes. Acta Paediatr 2007;96:638-43.
7. Conte E, Chiarelli F. Il trattamento del testicolo ritenuto. Medico e Bambino 2007;26:573-9.
8. Lee PA. Fertility after cryptorchidism: epidemiology and other outcome studies. Urology 2005;66:427-31.
9. Lee PA, Coughlin MT. Leydig cell function after cryptorchidism: evidence of the beneficial result of early surgery. J Urol 2002;167: 1824-7.
10. Andersson AM, Jørgensen N, Frydelund- Larsen L, Rajpert-De Meyts E, Skakkebaek NE. Impaired Leydig cell function in infertile men: a study of 357 idiopathic infertile men and 318 proven fertile controls. J Clin Endocrinol Metab 2004;89:3161-7.
11. Giwercman A, Bruun E, Frimodt-Møller C, Skakkebaek NE. Prevalence of carcinoma in situ and other histopathological abnormalities in testes of men with a history of cryptorchidism. J Urol 1989;42:998-1001, discussion 1001-2.
12. Møller H. Epidemiological studies of testicular germ cell cancer. Thames Cancer Registry, Thesis, King’s College London, 2001.
13. Dieckmann KP, Pichlmeier U. Clinical epidemiology of testicular germ cell tumors. World J Urol 2004;22:2-14.
14. Gapany C, Frey P, Cachat F, et al. Management of cryptorchidism in children: guidelines. Swiss Med Wkly 2008;138:492-8.
15. Marchetti F, Bua J, Tornese G, Toffol G, a nome del Gruppo di Coordinamento dello Studio. La gestione del bambino con testicolo ritenuto: dalla pratica clinica all’applicazionedelle linee guida. Protocollo di studio. Medico e Bambino pagine elettroniche 2008;11(5); http://www.medicoebambino.com/?id=RI080 5_10.html
16. Acerini CL, Miles HL, Dunger DB, Ong KK, Hughes IA. The descriptive epidemiology of congenital and acquired cryptorchidism in a UK infant cohort. Arch Dis Child 2009;94: 868-72.
17. Boisen KA, Kaleva M, Main KM, et al. Difference in prevalence of congenital cryptorchidism in infants between two Nordic countries. Lancet 2004;363:1264-9.
18. Thayyil S, Shenoy M, Agrawal K. Delayed orchidopexy: failure of screening or ascending testis. Arch Dis Child 2004;89:890.
19. Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Human Reprod (Oxford) 2001;16:972-8.
20. Taskinen S, Hovatta O, Wikström S. Early treatment of cryptorchidism, semen quality and testicular endocrinology. J Urol 1996;156: 82-84.
21. Andersson AM, Petersen JH, Jørgensen N, Jensen TK, Skakkebaek NE. Serum inhibin B and follicle-stimulating hormone levels as tools in the evaluation of infertile men: significance of adequate reference values from proven fertile men. J Clin Endocrinol Metab 2004;89:2873-9.
22. Lee PA, Coughlin MT. Leydig cell function after cryptorchidism: evidence of the beneficial result of early surgery. J Urol 2002;167: 1824-7.
23. Coughlin MT, Bellinger MF, Lee PA. Age at unilateral orchiopexy: effect on hormone levels and sperm count in adulthood. J Urol 1999;162:986-8.
24. Canavese F, Mussa M, Cortese MG, et al. Sperm Count of young men surgically treated for cryptorchidism in the first and second year of life: fertility is better in children treated at a younger age. Eur J Pediatr Surg 2009;19:388- 91.
25. Tasian GE, Hittelman AB, Kim GE, Di Sandro MJ, Baskin LS. Age at orchiopexy and testis palpability predict germ and Leydig celle loss: clinical predictors of adverse hystological features of cryptorchidism. J Urol 2009;182: 704-9.
26. Ritzén EM. Undescended testes: a consensus on management. Eur J Endocrinol 2008;159:S87-S90.
27. Pettersson A, Richiardi L, Nordenskjold A, Kaijser M, Akre O. Age at surgery for undescended testis and risk of testicular cancer. N Engl J Med 2007;356:1835-41.
28. Giwercman A, Grindsted J, Hansen B, Jensen OM, Skakkebaek NE. Testicular cancer risk in boys with maldescended testis: a cohort study. J Urol 1987;138:1214-6.
29. Herrinton LJ, Zhao W, Husson G. Management of cryptorchism and risk of testicular cancer. Am J Epidemiol 2003;157:602-5.
30. Pottern LM, Brown LM, Hoover RN, et al. Testicular cancer risk among young men: role of cryptorchidism and inguinal hernia. J Natl Cancer Inst 1985;74:377-81.
31. Rørth M, Rajpert-De Meyts E, et al. Carcinoma in situ in the testis. Scand J Urol Nephrol 2000;34 (Suppl 205):166-86.
32. Johnson KJ, Ross JA, Poynter JN, Linabery AM, Robison LL, Shu XO. Paediatric germ cell tumours and congenital abnormalities: a Children’s Oncology Group study. Br J Cancer 2009;101:518-21.
33. Wood HM, Elder JS. Cryptorchidism and testicular cancer: separating fact from fiction. J Urol 2009;181:452-61.
34. Kollin C, Karpe B, Hesser U, Granholm T, Ritzen EM. Surgical treatment of unilaterally undescended testes: testicular growth after randomization to orchiopexy at age 9 months or 3 years. J Urol 2007;178:1589-93.
35. Heiskanen P, Billig H, Toppari J, et al. Apoptotic cell death in the normal and cryptorchid human testis: the effect of human chorionic gonadotropin on testicular cell survival. Pediatr Res 1996;40:351-6.
36. Dunkel L, Taskinen S, Hovatta O, Tilly JL, Wikström S. Germ cell apoptosis after treatment of cryptorchidism with human chorionic gonadotropin is associated with impaired reproductive function in the adult. J Clin Invest 1997;100:2341-6.
37. Cortes D, Thorup J, Visfeldt J. Hormonal treatment may harm the germ cells in 1 to 3- year-old boys with cryptorchidism. J Urol 2000;163:1290-2.
38. Pirgon O, Atabek ME, Oran B, Suleymanoglu S, Meral C. Treatment with human chorionic gonadotropin induces left ventricular mass in cryptorchid boys. J Pediatr Endocrinol Metab 2009;22:449-54.
39. Gugliemi M, Pocecco M. Criptorchidismo, fimosi, varicocele. Andrologia a due voci. Medico e Bambino 1997;16:573-6.
40. Messineo A. Il testicolo ritenuto. Il punto di vista del chirurgo pediatra. Medico e Bambino 2002;21:119.
41. Raimondi F, Bussi M, Capasso L, et al. Caratteristiche alla nascita, evoluzione e terapia del testicolo ritenuto in 7199 neonati. Medico e Bambino 2002;21:116-9.
42. Barthold JS, González R. The epidemiology of congenital cryptorchidism, testicular ascent and orchiopexy. J Urol 2003;170:2396- 401.
43. McCabe JE, Kenny SE. Orchidopexy for undescended testis in England: is it evidence based? J Pediatr Surg 2008;43:353-7.
Corrispondenza: marchetti@burlo.trieste.it